Immune Globulin Articles
While these obscure, life-saving treatments are used to treat vastly different diseases, the common denominator they share is that each is made from plasma with a specialized high-titer antibody that provides short-term passive immunity.
During the past three decades,IVIG has proven an effective treatment for a wide range of autoimmune diseases, and it is now believed that IVIG may have clinical uses for a broader range of medical conditions.
With the FDA approval of SCIG therapy in 2006, many patients now have the choice between SCIG and IVIG infusions. Understanding the differences between the two treatment modalities will help healthcare providers recommend the right one for their patients.
As plasma protein therapies evolve to satisfy the world’s demand, the volume and costs of the therapies produced is dictated by which of the therapies is in highest demand.
Unpredictable fluctuation in supply and demand, combined with the current reimbursement model, is the root of the problem of affordableIG treatment.
Immune globulin is a standard of care for both FDA-approved and non-FDA-approved indications, and a growing body of research now shows promise for treating other diseases.